-transparent.png){kind=logo}
The referral of a patient with features of Cushing's syndrome but with suppressed plasma cortisol and adrenocorticotrophic hormone concentrations prompted us to study the effect of medroxyprogesterone acetate (MPA) therapy on the adrenal axis. 11 women (aged 54-82 years) who were receiving 200-400 mg/day MPA were studied. Of these, four had subnormal plasma cortisol responses to a short synacthen test, and two more had borderline responses (30 min post-synacthen plasma cortisol results of 411 and 511 nmol/L). We conclude that suppression of the adrenal axis occurs relatively frequently in patients on MPA and that such patients should be checked for evidence of suppression before MPA therapy is withdrawn.
K J Malik, and
K Wakelin, and
S Dean, and
D H Cove, and
P J Wood
September 1997,
British journal of clinical pharmacology,
K J Malik, and
K Wakelin, and
S Dean, and
D H Cove, and
P J Wood
August 2022,
Journal of neuroendocrinology,
K J Malik, and
K Wakelin, and
S Dean, and
D H Cove, and
P J Wood
August 1985,
Annals of the rheumatic diseases,
K J Malik, and
K Wakelin, and
S Dean, and
D H Cove, and
P J Wood
October 1996,
Psychoneuroendocrinology,
K J Malik, and
K Wakelin, and
S Dean, and
D H Cove, and
P J Wood
July 1990,
Lancet (London, England),
K J Malik, and
K Wakelin, and
S Dean, and
D H Cove, and
P J Wood
January 2018,
Frontiers in endocrinology,
K J Malik, and
K Wakelin, and
S Dean, and
D H Cove, and
P J Wood
May 1976,
The Journal of clinical endocrinology and metabolism,
K J Malik, and
K Wakelin, and
S Dean, and
D H Cove, and
P J Wood
December 1977,
Journal of the National Medical Association,
K J Malik, and
K Wakelin, and
S Dean, and
D H Cove, and
P J Wood
April 2015,
Journal of neurosurgical anesthesiology,
K J Malik, and
K Wakelin, and
S Dean, and
D H Cove, and
P J Wood
August 1990,
BMJ (Clinical research ed.),
